CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $163.21M, lower than 95% of all stocks globally
- PositionReturn on equity is -238.9%, lower than 95% of its Biotechnology peers (median -21.7%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
163.21MUSDvs all stocks (USD)
Revenue (TTM)
18.42MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.5990xvs all stocks
52-Week Change
-9.43%vs all stocks
Market Capitalization
163.21MUSDvs all stocks (USD)
Enterprise Value
-5.43MUSDvs all stocks (USD)
Forward P/E
-2.10xvs Biotechnology peers
Price to Sales (TTM)
8.86xvs Biotechnology peers
Price to Book (MRQ)
15.64xvs Biotechnology peers
Enterprise to Revenue
-0.2950xvs Biotechnology peers
Enterprise to EBITDA
0.0430xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-2382.31%vs Biotechnology peers
Return on Assets (TTM)
-25.71%vs Biotechnology peers
Return on Equity (TTM)
-238.85%vs Biotechnology peers
Revenue (TTM)
18.42MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1740USDUpdated Jul 17, 2026Quarterly Revenue Growth
-71.50%vs Biotechnology peers
Gross Profit (TTM)
-88.86MUSDvs all stocks (USD)
EBITDA (TTM)
-127.49MUSDvs all stocks (USD)
Net Income (TTM)
-125.39MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-71.53%vs Biotechnology peers
Operating Cash Flow (TTM)
-173.06MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-119.11MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
21.05MUSDFY2025 · Dec 31, 2025Operating Income
-156.01MUSDvs all stocks (USD)
Pre-tax Income
-142.76MUSDFY2025 · Dec 31, 2025Income Tax Expense
168.00KUSDFY2025 · Dec 31, 2025Net Income
-142.93MUSDFY2025 · Dec 31, 2025EBIT
-156.01MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-146.35MUSDFY2025 · Dec 31, 2025Research & Development
123.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
53.99MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.39USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.39USDFY2025 · Dec 31, 2025Basic Shares Outstanding
103.00MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
103.00MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-142.93MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-179.84MUSDFY2025 · Dec 31, 2025Free Cash Flow
-179.88MUSDDerived from operating cash flow minus capital expenditure. This filing charges 9.66M of depreciation against 41K of capital expenditure, and its own free-cash-flow line reads -184.07M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
67.65MUSDFY2025 · Dec 31, 2025Interest Paid
855.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-142.93MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
9.66MUSDFY2025 · Dec 31, 2025Stock-based Compensation
26.66MUSDFY2025 · Dec 31, 2025Other Non-cash Items
293.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-524.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-73.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-41.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-271.88MUSDFY2025 · Dec 31, 2025Sale of Investments
468.52MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
196.60MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
19.98MUSDFY2025 · Dec 31, 2025Shares Outstanding
111.03MSharesUpdated Jul 17, 2026Float Shares
83.80MSharesUpdated Jul 17, 2026Shares Short
5.72MSharesUpdated Jul 17, 2026Short Ratio
5.79daysvs all stocks
Short % of Shares Outstanding
5.45%vs all stocks
% Held by Insiders
9.67%vs all stocks
% Held by Institutions
82.20%vs all stocks
Total Cash (MRQ)
206.52MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.86USDUpdated Jul 17, 2026Total Debt (MRQ)
34.55MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
3.33xvs Biotechnology peers
Current Ratio (MRQ)
5.25xvs Biotechnology peers
Book Value per Share (MRQ)
0.0940USDUpdated Jul 17, 2026Total Assets
293.24MUSDvs all stocks (USD)
Total Current Assets
266.45MUSDFY2025 · Dec 31, 2025Total Liabilities
262.59MUSDFY2025 · Dec 31, 2025Total Non-current Assets
26.79MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
193.09MUSDFY2025 · Dec 31, 2025Total Current Liabilities
69.50MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
65.80MUSDFY2025 · Dec 31, 2025Other Short-term Investments
190.22MUSDFY2025 · Dec 31, 2025Accounts Payable
1.69MUSDFY2025 · Dec 31, 2025Short-term Debt
9.42MUSDFY2025 · Dec 31, 2025Deferred Revenue
6.68MUSDFY2025 · Dec 31, 2025Long-term Debt
26.81MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.74MUSDFY2025 · Dec 31, 2025Common Stock (Book)
11.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-972.06MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
30.65MUSDvs all stocks (USD)
52-Week Low
1.09USDUpdated Jul 17, 202652-Week High
3.40USDUpdated Jul 17, 202652-Week Change
-9.43%vs all stocks
Beta
0.5990xvs all stocks
50-Day MA
1.93USDUpdated Jul 17, 2026200-Day MA
1.98USDUpdated Jul 17, 2026Avg 10-Day Volume
549.54KSharesUpdated Jul 17, 2026Avg 30-Day Volume
810.92KSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-1.19USDUpdated Jul 17, 2026Other Income / Expense
13.25MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -238.9%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -2.39Industry median: -0.22Industry P5: -1.66Peers compared: 261
Debt-to-equity is 3.33×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 3.33Industry median: 0.09Industry P95: 0.88Peers compared: 261
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 206,515,008Total Debt (USD): 34,548,000Debt-to-Equity: 3.33
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $163.21M, lower than 95% of all stocks globallySignificant
Market cap (USD): 163,207,024Global P5: 269,387,740.27
Revenue is $18.42M, lower than 95% of all stocks globallySignificant
Revenue (USD): 18,417,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Journey Medical Corp
Tier 1ProductionApproval-Gated PipelineRule
Mycenax Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sensorion SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Graphy Inc.
Tier 1ProductionApproval-Gated PipelineRule
Asterasys Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chill Brands Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
ADC Therapeutics S.A.
Tier 1ProductionApproval-Gated PipelineRule
S Biomedics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
EKF Diagnostics Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
HLB Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Great Rich Technologies Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
American Battery Technology Company
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
ADC Therapeutics S.A.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated